NO20055666L - HSA-frie, stabiliserte flytende utforminger av interferon - Google Patents

HSA-frie, stabiliserte flytende utforminger av interferon

Info

Publication number
NO20055666L
NO20055666L NO20055666A NO20055666A NO20055666L NO 20055666 L NO20055666 L NO 20055666L NO 20055666 A NO20055666 A NO 20055666A NO 20055666 A NO20055666 A NO 20055666A NO 20055666 L NO20055666 L NO 20055666L
Authority
NO
Norway
Prior art keywords
interferon
hsa
free
stabilized liquid
configurations
Prior art date
Application number
NO20055666A
Other languages
English (en)
Other versions
NO335674B1 (no
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20055666L publication Critical patent/NO20055666L/no
Publication of NO335674B1 publication Critical patent/NO335674B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

En stabilisert HSA-fii flytende farmasøytisk sammensetning som omfatter et interferon (IFN) beskrives, hvori utformingen er en løsning som omfatter en buffer, et overflateaktivt middel, et isotonisitetsmiddel og en antioksidant. Interferonet er fortrirmsvis himiant rekombinant IFN-beta.
NO20055666A 2003-05-01 2005-11-30 HSA-frie, stabiliserte flytende utforminger av interferon-beta NO335674B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03101210 2003-05-01
US53016903P 2003-12-17 2003-12-17
PCT/EP2004/004806 WO2004096263A2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilized interferon liquid formulations

Publications (2)

Publication Number Publication Date
NO20055666L true NO20055666L (no) 2005-11-30
NO335674B1 NO335674B1 (no) 2015-01-19

Family

ID=36908159

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055666A NO335674B1 (no) 2003-05-01 2005-11-30 HSA-frie, stabiliserte flytende utforminger av interferon-beta

Country Status (29)

Country Link
US (1) US8309069B2 (no)
EP (1) EP1617861B1 (no)
JP (2) JP4870550B2 (no)
KR (1) KR101116058B1 (no)
CN (1) CN1816347B (no)
AR (1) AR044147A1 (no)
AU (2) AU2004233603B2 (no)
BR (1) BRPI0410488B8 (no)
CA (1) CA2521560A1 (no)
DK (1) DK1617861T3 (no)
EA (2) EA009995B1 (no)
ES (1) ES2417061T3 (no)
HK (1) HK1088847A1 (no)
HR (1) HRP20130512T1 (no)
IL (1) IL171709A (no)
ME (1) ME00404B (no)
MX (1) MXPA05011718A (no)
MY (1) MY151121A (no)
NO (1) NO335674B1 (no)
NZ (2) NZ566625A (no)
PL (1) PL1617861T3 (no)
PT (1) PT1617861E (no)
RS (1) RS52869B (no)
SG (1) SG159389A1 (no)
SI (1) SI1617861T1 (no)
TW (1) TWI272948B (no)
UA (2) UA80331C2 (no)
WO (1) WO2004096263A2 (no)
ZA (2) ZA200508124B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1691825E (pt) * 2003-12-11 2011-10-12 Ares Trading Sa Formulações líquidas de interferão estabilizadas
EA012205B1 (ru) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
CA2567310A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Stabilized interferon liquid formulations
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
PT1951395E (pt) * 2005-09-14 2012-03-21 Ares Trading Sa Método para a determinação quantitativa de poloxâmeros
KR20090019810A (ko) 2006-05-24 2009-02-25 라보라뚜와르 세로노 에스. 에이. 다발성 경화증 치료를 위한 클라드리빈 요법
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
WO2008065752A1 (fr) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Agent immunothérapeutique contenant un arndi en tant que principe actif
ES2617063T3 (es) 2007-03-30 2017-06-15 Xisle Pharma Ventures Trust Composición de vesículas lipídicas bifásicas y método para tratar la displasia de cuello uterino por suministro intravaginal
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
US9138403B2 (en) 2007-12-20 2015-09-22 Merck Serono Sa PEG-interferon-beta formulations
CA2888442A1 (en) 2012-10-26 2014-05-01 Lupin Limited Stable pharmaceutical composition of peginterferon alpha-2b
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
JP6445169B2 (ja) * 2014-09-23 2018-12-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5858001A (en) * 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
CN1733296B (zh) 1996-12-24 2010-05-26 拜奥根Idec马萨诸塞公司 稳定的液体干扰素制剂
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
ES2223017T5 (es) * 1997-09-23 2010-10-15 Rentschler Biotechnologie Gmbh Formulaciones liquidas de un interferon beta.
EP1037995A1 (en) * 1997-12-08 2000-09-27 Genentech, Inc. Human interferon-epsilon: a type 1 interferon
PL193352B1 (pl) 1998-04-28 2007-02-28 Applied Research Systems Koniugat poliol-interferon ß, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
SK287967B6 (sk) * 1998-05-11 2012-07-03 Basf Aktiengesellschaft Process for preparing benzaldoximes
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
PT1691825E (pt) * 2003-12-11 2011-10-12 Ares Trading Sa Formulações líquidas de interferão estabilizadas
EA012205B1 (ru) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков

Also Published As

Publication number Publication date
JP4870550B2 (ja) 2012-02-08
EA009995B1 (ru) 2008-06-30
RS20050821A (en) 2007-12-31
ES2417061T3 (es) 2013-08-05
NO335674B1 (no) 2015-01-19
TWI272948B (en) 2007-02-11
EP1617861A2 (en) 2006-01-25
EA200800327A1 (ru) 2008-10-30
HRP20130512T1 (hr) 2013-07-31
UA94032C2 (ru) 2011-04-11
ZA200508124B (en) 2009-02-25
EA200501699A1 (ru) 2006-06-30
BRPI0410488B1 (pt) 2021-06-22
SG159389A1 (en) 2010-03-30
KR101116058B1 (ko) 2012-04-12
AU2009201261A1 (en) 2009-04-23
MXPA05011718A (es) 2006-01-23
AU2004233603A1 (en) 2004-11-11
EP1617861B1 (en) 2013-05-29
AU2004233603B2 (en) 2009-02-26
DK1617861T3 (da) 2013-07-29
WO2004096263A2 (en) 2004-11-11
RS52869B (sr) 2013-12-31
US20070059285A1 (en) 2007-03-15
HK1088847A1 (en) 2006-11-17
JP2006525280A (ja) 2006-11-09
AR044147A1 (es) 2005-08-24
MEP60408A (en) 2011-05-10
ME00404B (me) 2011-10-10
CN1816347A (zh) 2006-08-09
CN1816347B (zh) 2010-07-21
PT1617861E (pt) 2013-08-28
NZ542912A (en) 2008-04-30
TW200503754A (en) 2005-02-01
KR20060011976A (ko) 2006-02-06
BRPI0410488B8 (pt) 2021-09-08
JP2011225599A (ja) 2011-11-10
SI1617861T1 (sl) 2013-09-30
NZ566625A (en) 2010-02-26
PL1617861T3 (pl) 2013-10-31
IL171709A (en) 2016-03-31
US8309069B2 (en) 2012-11-13
JP5346065B2 (ja) 2013-11-20
UA80331C2 (en) 2007-09-10
ZA200708484B (en) 2008-10-29
CA2521560A1 (en) 2004-11-11
WO2004096263A3 (en) 2004-12-02
BRPI0410488A (pt) 2006-06-13
MY151121A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
NO20055666L (no) HSA-frie, stabiliserte flytende utforminger av interferon
NO20065860L (no) Stabiliserte flytende interferonformuleringer
DK1143989T3 (da) Exendiner til glucagonundertrykkelse
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
NO20063108L (no) Stabiliserte, flytende interferonformuleringer
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
AR037131A1 (es) Formulaciones de jarabe de ribavirina
DK1273301T3 (da) Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration
CY1110841T1 (el) Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4)
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof
NO20065853L (no) Hydrogelinterferonformuleringer